Messenger RNA vaccine development relies on foundational breakthroughs in chromatography, transforming how scientists purify unstable nucleic acids for rapid pharmaceutical deployment. Because natural cellular mRNA degrades rapidly via ubiquitous ribonuclease enzymes, early virology research faced severe hurdles in isolating pure genetic material without metal contamination or structural damage.
Chromatography Innovations Drive RNA Stability
The pursuit of stable mRNA production required adapting techniques originally designed for small molecule analysis and DNA separation. Mikhail Tswett first described chromatography in 1903, establishing a baseline separation science that evolved significantly over the twentieth century. Professor Csaba Horváth of Yale University designed uniform, nonporous silica beads in 1969, introducing the pellicular support concept with an impermeable core and a thin, porous active layer to minimize analyte diffusion limitations.
Building on these chromatographic principles, Guenther K. Bonn at the University of Linz and later the University of Innsbruck focused on polymer-based substrates required for acid- and base-stable ion chromatography. Douglas T. Gjerde developed non-suppressor ion chromatography technology during his graduate studies at Iowa State University alongside Professor James Fritz and visiting professor Gabriella Schmuckler, later commercializing polymer columns through his company Sarasep, Inc.
Polymer Media and Monodisperse Particles
A major turning point for macromolecule separation emerged when Professor John Ugelstad at the Norwegian Institute of Technology developed a method to prepare monodisperse polymer particles. Incorporating metal into the interior of these beads enabled magnetic separation via Dynabeads. Collaborating with students Christian Huber and Peter Oefner, Bonn adapted this approach to produce monodisperse polymer seeds incorporating divinylbenzene monomers.
These cured, C18-alkylated beads provided uniform, pH-stable media significantly harder than standard polymer alternatives, allowing successful packing into stainless-steel high-performance liquid chromatography columns. When initial tests with small analytes showed limited retention due to low surface area, researchers recognized that larger organic molecules like double-stranded DNA bound much more strongly to the new resin.
These specialized stationary phases and metal-free purification methods enabled subsequent advances by Katalin Karikó and Drew Weissman. Their foundational work later allowed manufacturers such as Pfizer-BioNTech and Moderna to synthesize pure, stable mRNA supplies rapidly, meeting regulatory standards for clinical deployment during the COVID-19 pandemic.
Related reading